Skip to content

The clinical outcome of MPA in Primed-progesterone ovarian stimulation protocol for active endometriosis patients undergoing IVF cycle

The clinical outcome of MPA in Primed-progesterone ovarian stimulation protocol for active endometriosis patients undergoing IVF cycle

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17010924
Enrollment
Unknown
Registered
2017-03-19
Start date
2017-03-19
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

1:HMG+MPA
2:ultra-long GnRHa+HMG

Sponsors

The Shanghai Ninth People's Hospital affiliated of Shanghai JiaoTong University of medical school
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. patients with active endometriosis aged 20-40 years; 2. regular ovulation, FSH less than 10IU/L; 3. AFC 5-20; 4. clinical manifestations and auxiliary examination of active endometriosis: (1) endometriotic cysts recurrence after laparoscopy or laparotomy before IVF; (2) increased dysmenorrhea or tenderness nodules by gynecological examination after endometriotic cysts surgery by laparoscopy or laparotomy before IVF; (3) increased CA125 after endometriotic cysts surgery by laparoscopy or laparotomy before IVF; (4) ovarian endometriomas that were aspirated and identified as multiple chocolate cysts (=1-3cm) or a single chocolate cyst(=3cm)(unilateral or bilateral) during ovulation monitoring or at the time of oocyte retrieval.

Exclusion criteria

Exclusion criteria: 1. Hydrosalpinx; 2. polycystic ovarian syndrome (PCOS); 3. adenomyosis (AM) diagnosed by laparoscopic or laparotomy or disordered myometrial echo confirmed by ultrasound examination, mild adenomyosis by MRI diagnosis; 4. uterine malformations; 5. severe intrauterine adhesions; 6. endometrium thickness <7mm on transplantation day; 7. recurrent abortions =3; 8. clinically significant systemic disease such as renal failure.

Design outcomes

Primary

MeasureTime frame
oocyte retrieval rate;maturation rate;viable embryo rate;implantation rate;clinical pregnancy rate;

Secondary

MeasureTime frame
cancellation rate;

Countries

China

Contacts

Public ContactYanping Kuang

Shanghai 9th People's Hospital

kuangyanp@126.com+86 021-53078080

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026